Incremental value of 99mTc-HYNICTOC SPECT/CT over whole-body planar scintigraphy and SPECT in patients with neuroendocrine tumours
Authors:
- Stanko TežakSTStanko Težak
- Mate TrogrlicMTMate Trogrlic
- 1 May 2017
- journal article
- research article
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 56 (03) , 97-107
Abstract
Als Standes- und Fachorgan von hohem wissenschaftlichen Anspruch befasst sich die CME-zertifizierte Nuklearmedizin mit Diagnostik und Therapie in der Nuklearmedizin und dem StrahlenschutzKeywords
This publication has 32 references indexed in Scilit:
- SPECT-CT in routine clinical practiceNuclear Medicine Communications, 2012
- Specificity and sensitivity of 99mTc-EDDA/HYNIC-Tyr3-octreotide (99mTc-TOC) for imaging neuroendocrine tumorsNuclear Medicine Communications, 2012
- Gallium-68-DOTA-NOC PET/CT of Patients With Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Single-Center StudyAmerican Journal of Roentgenology, 2011
- Patient-Specific Radiation Dosimetry of 99mTc-HYNIC-Tyr3-Octreotide in Neuroendocrine TumorsJournal of Nuclear Medicine, 2011
- 68Ga-labeled DOTA-Peptides and 68Ga-labeled Radiopharmaceuticals for Positron Emission Tomography: Current Status of Research, Clinical Applications, and Future PerspectivesSeminars in Nuclear Medicine, 2011
- Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinationsNuklearmedizin-Nuclear Medicine, 2009
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- Biokinetics and dosimetry in patients of 99mTc-EDDA/HYNIC-Tyr3-octreotide prepared from lyophilized kitsApplied Radiation and Isotopes, 2006
- Epidemiology of Neuroendocrine TumoursNeuroendocrinology, 2004
- Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosisJournal of Pharmaceutical Sciences, 2004